Skip to main content

Advertisement

Table 1 Clinical characteristics of the cohort

From: Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Patients` characteristics (n = 35) median IQR range
Age at first diagnosis of melanoma (years) 55 47–70 17–79
Time between primary diagnosis and first distant metastasis (months) 17 5–43 0–241
Time between start of combined immunotherapy and first staging (days) 69 49–80 12–108
Time between start of combined immunotherapy and onset of severe adverse events (days) 42 21–61 11–126
   no. patients %
Sex
 Female   16 46
 Male   19 54
Melanoma type
 Cutaneous   20 57
 Occult   6 17
 Uveal   4 11
 Acral   3 9
 Mucosal   2 6
BRAF mutation
 BRAF v600 positive   16 46
 BRAF v600 negative   19 54
Systemic treatment before combined immunotherapy
 None – combined immunotherapy as first line   22 63
 Targeted therapy   10 29
 PD1 antibody   3 9
LDH at start of combined immunotherapy
 LDH elevated   14 40
 LDH normal   21 60
Metastasis at start of combined immunotherapy
 Presence of lung metastases   19 54
 Presence of brain metastases   12 34
 Presence of liver metastases   10 29
AJCC (2017) stage
 M1a/M1b   11 31
 M1c   12 34
 M1d   12 34
Cycles of combined immunotherapy
 1 cycle   3 9
 2 cycles   7 20
 3 cycles   8 23
 4 cycles   17 49
Response to combined immunotherapy
 Response   15 43
-- complete response   4 11
 Progressive disease   20 57
Adverse events CTCAE 3–4   22 63
Origin of tissue sequenced
 Lymph node metastasis   15 43
 Other metastasis   18 51
 Primary melanoma   2 6
Status of tissue sequenced
 Tissue therapy naïve   31 89
 Tissue pretreated   4 11